Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?
Translational Breast Cancer Research · 2026-04 · 7 · 22-22
DOI: 10.21037/tbcr-25-57 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Breast Cancer Research, 2026-04. Verfasst von Harry D Bear. Beteiligte Einrichtung: Departments of Surgery and Microbiology & Immunology and the Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
trastuzumab-emtansine for advanced HER2 + breast cancer also did not show any improvement compared to trastuzumab-emtansine alone (12). The recently reported Neo-HIP trial compared paclitaxel (T) + trastuzumab (H) + pertuzumab (P) vs. THP + pembrolizumab (THP-K) vs. TH-K in the neoadjuvant setting (13). Adding pembrolizumab to THP increased the total pCR rate from 51.9% to 67.2%. The arm without pertuzumab was discontinued because of a low pCR rate (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Surgery and Microbiology & Immunology and the Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
ORCID-Profile: Harry D Bear
Zitieren
APA
Bear, H. D. (2026). Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?. Translational Breast Cancer Research, 7, 22-22. https://doi.org/10.21037/tbcr-25-57
Vancouver
Bear HD. Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?. Translational Breast Cancer Research. 2026;7:22-22. doi:10.21037/tbcr-25-57
BibTeX
@article{Bear2026,
author = {Bear, Harry D},
title = {Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?},
journal = {Translational Breast Cancer Research},
year = {2026},
volume = {7},
pages = {22--22},
doi = {10.21037/tbcr-25-57}
}
EUVIMED